There are no clinically significant pharmacokinetic interactions between nucleoside reverse transcriptase inhibitors
(NRTIs) and rifampicin-based TB treatment.
Other factors associated with severe hepatotoxicity in this study were use of nevirapine-containing drugs, which were associated in those taking a nonnucleoside reverse transcriptase inhibitor
with both early (OR 4.
In addition, the company announced plans to initiate a Phase II study for a proprietary investigational next generation non-nucleoside reverse transcriptase inhibitor
The most common combinations of two nucleoside reverse transcriptase inhibitors
were didanosine plus stavudine (52% of patients) and zidovudine plus lamivudine (42%).
A novel nucleoside reverse transcriptase inhibitor
candidate - EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) - has shown antiviral activity toward highly resistant HIV strains.
New precautions have been added to the labeling for Viramune, a non-nucleoside reverse transcriptase inhibitor
(NNRTI or "non-nuke").
The four new anti-HIV drugs that came out in 2003 are Fuzeon, part of a new class of drugs called entry inhibitors or fusion inhibitors; the protease inhibitors Reyataz and Lexiva; and the reverse transcriptase inhibitor
High AST also was predictive of severe hepatotoxicity in the first 6 months of therapy among patients using a non-nucleoside reverse transcriptase inhibitor
ATRIPLA contains 600 mg of efavirenz, a non-nucleoside reverse transcriptase inhibitor
(NNRTI), 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate, both nucleoside reverse transcriptase inhibitors
Additionally, the company announced plans to initiate a Phase II study for a proprietary investigational next generation non-nucleoside reverse transcriptase inhibitor
STOCRIN is a once-daily, non-nucleoside reverse transcriptase inhibitor
(NNRTI) used in combination treatment for HIV.
Emtriva is a nucleoside reverse transcriptase inhibitor
(NRTI or nuke).
This is a very active antiretroviral of the NNRTI class (non-nucleoside reverse transcriptase inhibitor
-- the same class as efavirenz, nevirapine, and delavirdine, the three NNRTI drugs currently approved in the U.
STOCKHOLM, Sweden -- Medivir AB (STO:MVIRB), Sweden, and Guangdong Lantai Viewland Pharmaceutical, China, announced today the signing of a licensing agreement on MIV-160 (MV026048), a non-nucleoside HIV reverse transcriptase inhibitor
(NNRTI) in late pre-clinical development.
The FDA approved on February 1, 2002, a new formulation of Sustiva (efavirenz), a non nucleoside reverse transcriptase inhibitor
for the treatment of HIV infection.